SEO URLwww.firestrike.ai/deals/amicus-therapeutics-biomarin-acquisition-2026-5
acquisitionAnnounced · Feb 7, 2026PharmaceuticalsSource · CredibleArticle · Factual
BioMarin acquires Amicus Therapeutics
David Najork · Founding Software Engineer
Announced · Updated · 1 min read
Deal value
$4.7B
Target
Amicus Therapeutics
NASDAQ: FOLD · Princeton, New Jersey
Acquirer
BioMarin
Full Acquisition
Status
Pending
BioMarin agreed to acquire Amicus Therapeutics. Reported deal value: $4.7B. Status: Pending. Sector: Pharmaceuticals. Target headquarters context: Princeton, New Jersey, United States.
This page summarizes publicly available information about the transaction as of 2026-02-07. Figures and status may change as filings and press coverage update.
Barclays Initiates Coverage on BioMarin Pharmaceutical , with an Overweight Call One of those acquisition targets in the pipeline is Amicus Therapeutics , Inc. BioMarin recently finalized the syndication of a $2 billion senior secured term loan B
Deal timeline
Announced
Feb 7, 2026 · finance.yahoo.com
Additional milestones (proxy, vote, close) appear as filings and press updates are indexed.
Sector context
This transaction is classified in Pharmaceuticals with a reported deal value of $4.7B. Figures and status may change as sources update.
Sources: finance.yahoo.com · Primary article · FireStrike proprietary index